MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine

SAN DIEGO, July 3, 2018 -- (Healthcare Sales & Marketing Network) -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical stage oncology drug development company has granted to Y-mAbs Therapeutics, Inc., a privately held clinical stage biopharmac... Biopharmaceuticals, Oncology, Licensing MabVax Therapeutics, Y-mAbs Therapeutics, neuroblastoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news